Research Grants

Home / Research Grants

The objective of the EAHAD Research Grants is to foster pre-clinical and clinical research collaborations in Europe and to support scientific projects aimed at improving the care of patients with inherited and acquired bleeding disorders.


The grant application cycle runs yearly. For the 2022 cycle, please click here

2021 Recipients


Michelle Lai, PhD | University of Pisa – Dipartimento di Ricerca Traslazionale e delle Nuove Tecnologie in Medicina e Chirurgia
“Engineering and production of recombinant factor eight with long half-life and high coagulant activity”

Lay Summary:
The present proposal aims the selection of mutated FVIII (mFVIII) with improved stability, half-life and functional activity compared to products already on the market. Moreover, we aim to find novel mFVIII that exhibit less immunogenicity.

Project duration: January 2022-January 2024

Grant amount: € 25.000


Ilaria Cutica, PhD | Fondazione Luigi Villa, Ospedale Maggiore Policlinico
“Knowledge and attitudes of haemophilic patients toward gene therapy (KAHaGeT)”

Lay Summary:
Haemophilia gene therapy is in late stages of development and hopefully it will get market authorization soon. However, not all haemophiliac patients know the functioning of gene therapy, nor its risks and benefits. For this reason, patients may feel disoriented by their doctor’s proposal to undergo gene therapy and have difficulty making choices. This study investigates the level of literacy about gene therapy and the attitudes toward it in a cohort of Italian haemophilic patients, focusing on their information needs, priorities and concerns, in order to identify the main factors associated with their willingness to accept gene therapy.
A better understanding of all factors that play a role in decisions about such treatment will help clinicians to effectively communicate with their patients about this topic, and to better respond to their needs in order to support their decision process.

Project duration: October 2021-October 2022

Grant amount: € 25.000

2020 Recipient


Jose Rivera, PhD | Hospital Universitario Morales Meseguer, Centro, Regional de Hemodonación, Universidad de Murcia, Spain
“Development of a novel gene therapy approach for Glanzmann thrombasthenia (GT): Assessment in CRISPR GT cell model, GT patient progenitor cells, and NBSGW immunodeficient mice”

Lay Summary:
This project will evaluate a gene rescue approach as an alternative therapy for Glanzmann thrombasthenia. The main objective is to prove that ex vivo genetic correction of patient’s HSC will correct the bleeding phenotype.

Project duration: February 2020-February 2022

Grant amount: € 50.000

2019 Recipients


Samantha Gouw MD, PhD | Amsterdam University Medical Center, The Netherlands
“Getting GRIP on Tolerance: The role of Fc Gamma Receptors in Immune tolerance to Protein therapeutics”

Lay Summary:
Antibodies against protein drugs impair effective treatment. Strategies to get rid of these antibodies fail in many patients. In haemophilia patients, this project aims to clarify the underlying reasons and to find genetic factors that can be used to predict who will and will not get rid of these antibodies.

Project duration: July 2019-January 2021

Grant amount: € 50.000




Nathalie Roussel, PhD, MSc, PT| Faculty of Medicine & Health Sciences, University of Antwerp, Belgium
“Towards a better understanding of ankle pain in haemophilia patients: A study examining the relationship between structure and function, taking pain mechanisms into account”

Lay Summary:
While pain is of major importance in many patients with haemophilia, pain assessment and treatment are not well developed in this population. This is the first study evaluating the structural and functional status of affected ankle joints combined with the local and central pain condition in patients with haemophilia in order to better understand the complexity of ankle pain.

Project duration: April 2019-April 2020

Grant amount: € 50.000


2018 Recipients


Alessandro Casini, MD | University Hospitals of Geneva, Geneva, Switzerland

“Interactions between fibrinogen variants and blood cells: towards a predictive model in congenital fibrinogen disorders” 

Lay Summary:
Patients suffering from congenital fibrinogen disorders often have an unpredictable clinical course. Developing methods, which allow the prediction of adverse outcomes, is crucial in order to tailor the best management for these patients. The aim of this project is to determine the interplay between fibrinogen, red blood cells and platelets through the study of the whole blood clot from patients with congenital fibrinogen disorders.


Project duration: October 2018-September 2019

Grant amount: € 45.000




Sébastien Lacroix-Desmazes, PhD, Research Director | INSERM, Centre de Recherche des Cordeliers 15, Paris, France

“High throughput generation and characterization of monoclonal anti-FVIII IgG from patients with hemophilia A”

Lay Summary:
Treatment of patients with hemophilia A by injection of therapeutic FVIII induces blocking anti-factor VIII antibodies in up to one patient out of three.
In this project, we will isolate the cells that produce anti-factor VIII antibodies from the blood of some patients and generate a large array of single recombinant anti-factor VIII antibodies. We will then establish the ID card of each of the anti-factor VIII antibodies. This will lead to the identification of prognostic markers for successful patient treatment, as well as the development of new treatments to prevent the appearance of or eliminate anti-factor VIII antibodies.


Project duration: March 2018-February 2020

Grant amount: €50,000


2017 Recipients


Johan Boender, MD | Erasmus University Medical Center, Rotterdam, the Netherlands

“Does ADAMTS13 influence the bleeding phenotype in von Willebrand disease?”


Project duration: April 2017-March 2018

Grant amount: €47,950



Roberta Palla, PhD | Fondazione Luigi Villa, Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy

“High throughput analysis of antibody binding profiles in previously untreated patients with severe haemophilia A”


Project duration: April 2017-March 2019

Grant amount: €50,000